Director Antibody Downstream Development United States
alnylam
About this role
The Director, Process Sciences oversees downstream process development, optimization, and characterization of antibody oligonucleotide conjugates. The role involves working with cross-functional teams and contract manufacturing organizations to support API manufacture, process transfer, and regulatory activities, with a focus on antibody and ADC technologies.
Skills
Qualifications
About alnylam
alnylam.comNew Relic is a SaaS observability and telemetry platform that helps engineering teams instrument, monitor, and troubleshoot applications and cloud infrastructure. It ingests metrics, events, logs, traces, and browser real-user data to deliver APM, distributed tracing, infrastructure monitoring, log management, synthetics, and RUM. The platform provides unified dashboards, alerting, anomaly detection, and root-cause analysis, plus integrations with cloud providers, services, and CI/CD tooling. Teams use New Relic to improve performance, accelerate incident response, and gain end-to-end visibility into customer experience and system health.
About alnylam
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Leadership Team
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
Unlock Company Insights
View leadership team, funding history,
and employee contacts for alnylam.
Salary
$197k – $267k
per year
More jobs at alnylam
Similar Jobs
Scientist III - Bioconjugation (ADC) Process Development
Exelixis
Director - Oligonucleotide Analytical Chemistry
Eli Lilly and Company
Director, Antibody Drug Conjugate
Exelixis
Associate Director, Bioconjugation & Delivery
Alloy Therapeutics
Sr. Scientist, Protein and Antibody Bioconjugation
Neurocrine Biosciences
Senior Scientist I, ADC/AOC Conjugation
AbbVie